share_log

Immunic And 2 Other Stocks Under $2 Insiders Are Buying

Immunic And 2 Other Stocks Under $2 Insiders Are Buying

Immunic和其他兩隻低於2美元的股票內部人士正在買入
Benzinga ·  02/29 10:40

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週三收盤下跌超過20點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。

OPKO Health

OPKO 健康

  • The Trade: OPKO Health, Inc. (NASDAQ:OPK) 10% owner Frost Gamma Investments Trust acquired a total of 500,000 shares an average price of $0.99. To acquire these shares, it cost around $496,150.
  • What's Happening: On Feb. 27, OPKO Health posted upbeat quarterly results.
  • What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.
  • 交易：OPKO Health, Inc.（納斯達克股票代碼：OPK）10％的所有者弗羅斯特·伽瑪投資信託基金 共收購50萬股股票 平均價格爲0.99美元。收購這些股票的成本約爲496,150美元。
  • 發生了什麼：2月27日，OPKO Health公佈了樂觀的季度業績。
  • OPKO Health的所作所爲：OPKO Health Inc是一家多元化的生物技術公司，經營藥物和診斷開發項目。

Immunic

免疫

  • The Trade: Immunic, Inc. (NASDAQ:IMUX) President and CEO Daniel Vitt acquired a total of 14,000 shares at at an average price of $1.31. To acquire these shares, it cost around $18,333.
  • What's Happening: On Feb. 22, Immunic reported a narrower-than-expected fourth-quarter loss.
  • What Immunic Does: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis.
  • 貿易：Immunic, Inc.（納斯達克股票代碼：IMUX）總裁兼首席執行官丹尼爾·維特 共收購了14,000股股票 平均價格爲1.31美元。收購這些股票的成本約爲18,333美元。
  • 發生了什麼：2月22日，Immunic公佈的第四季度虧損低於預期。
  • Immunic做什麼：Immunic Inc是一家臨床階段的生物製藥公司，正在開發一系列選擇性口服免疫療法，旨在治療慢性炎症和自身免疫性疾病，包括潰瘍性結腸炎、克羅恩氏病、復發緩解型多發性硬化症和牛皮癬。

Fresh Tracks Therapeutics

新曲目療法

  • The Trade: Fresh Tracks Therapeutics, Inc. (OTC:FRTX) 10% owner Exploration Capital, LLC acquired a total of 20,109 shares at an average price of $0.90. The insider spent around $18,098 to buy those shares.
  • What's Happening: The company's stock fell around 6% over the past month.
  • What Fresh Tracks Therapeutics Does: Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
  • 交易：Fresh Tracks Therapeutics, Inc.（場外交易代碼：FRTX）10% 的所有者勘探資本有限責任公司 共收購了20,109股股票 平均價格爲0.90美元。知情人士花費了約18,098美元購買了這些股票。
  • 發生了什麼：該公司的股票在過去一個月中下跌了約6％。
  • Fresh Tracks Therapeutics的所作所爲：Fresh Tracks Therapeutics Inc是一家處於臨床階段的製藥公司，致力於通過開發創新的差異化處方療法來改變患者的生活。


Don't forget to check out our premarket coverage here


別忘了在這裏查看我們的上市前報道

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論